Science
Chronic Lymphocytic Leukemia
Petra Langerbeins/touchoncology.com

CLL12 study supports using the watch-and-wait approach for early-stage CLL

Jonathan Friedberg, Director of Wilmot Cancer Institute, shared a recent article by Petra Langerbeins, et al. on X:

CLL12 study supports using the watch-and-wait approach as the standard of care for early-stage CLL, including high-risk patients.

Ongoing SWOG Cancer Research Network S1925 trial evaluates early venetoclax-based treatment for high risk patients.

Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial

Authors: Petra Langerbeins, et al.

CLL12 study supports using the watch-and-wait approach for early-stage CLL

cancer CLL CLL12 Jonathan Friedberg OncoDaily Oncology Petra Langerbeins S1925 trial SWOG Cancer Research Network venetoclax Wilmot Cancer Institute